表紙：ペプチド合成市場、産業動向と世界予測 (～2035年)：ペプチド合成方法別、化学合成タイプ別、受託製造組織の規模別、主要地域別

市場調査レポート

商品コード

1439188

ペプチド合成市場、産業動向と世界予測 (～2035年)：ペプチド合成方法別、化学合成タイプ別、受託製造組織の規模別、主要地域別

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions

出版日: 2024年01月17日 | 発行: Roots Analysis

| ページ情報: 英文 390 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 752,291円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,097,163円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,661,499円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,821,523円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ペプチド合成の市場規模は、2023年に25億米ドルとなりました。同市場は、2023年から2035年の予測期間中に5.46%のCAGRで拡大すると予測されています。

ペプチドは、細胞表面上の特定の受容体に結合するシグナル伝達分子として機能し、生理学的機能やさまざまな成分の代謝合成を調節する細胞内効果を開始します。代謝安定性、標的特異性、親和性の向上により、治療候補としての重要性が高まっています。小分子薬や生物製剤とは異なり、ペプチドベースの治療薬は、薬理学的調査、分析/プロセス開発、不純物調査、構造認識において独特の課題を抱えています。ペプチド合成市場は、ペプチド治療薬の人気により、近年大きく発展しました。現在、がん、慢性疼痛、糖尿病、HIV感染症、多発性硬化症、骨粗鬆症などのさまざまな慢性疾患の治療用として、80を超えるペプチド治療薬が世界中で承認されています。さらに、2015年以来、ペプチドベースの治療の治療効果を評価するために630以上の臨床試験が進行中です。さらに、調査活動の増加とペプチドベースの治療に対する需要により、開発者は能力を拡張し、製造装置をアップグレードするようになりました。

しかし、ペプチド合成は生産能力不足などの課題に直面しており、開発者はコストと市場投入までの時間を削減するために複雑な製造プロセスを契約サービスプロバイダーにアウトソーシングするようになっています。製薬企業やバイオテクノロジー企業は、ペプチド医薬品のバイオアベイラビリティを向上させ、合成効率を高めるための高度な技術プラットフォームを提供する受託製造組織（CMO）と積極的に連携しています。セマグルチドのジェネリック医薬品がペプチド合成市場に参入したことにより、アウトソーシング需要が急増しました。GLP-1ペプチドAPIの受託製造需要は、II型糖尿病や肥満などの代謝障害の治療における利点により、2017年から2023年にかけて年間37%の割合で顕著に増加しました。これらの要因は、近い将来、ペプチド合成市場における受託製造業者に有利な機会をもたらします。

当レポートでは、世界のペプチド合成市場について調査し、市場の概要とともに、ペプチド合成方法別、化学合成タイプ別、受託製造組織の規模別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 5.1 Comparison of Major Peptide Synthesizing Processes
Table 5.2 Chromatographic Techniques
Table 6.1 Comparison of Regulatory Landscape of China and India
Table 7.1 Peptide Therapeutics Contract API Manufacturers: List of Companies
Table 7.2 Peptide Therapeutics Contract API Manufacturers: Information on Type of API and Scale of Operation
Table 7.3 Peptide Therapeutics Contract API Manufacturers: Information on Type of Services Offered and Peptide Synthesis Method
Table 7.4 Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification and Type of Purification Technology Used
Table 7.5 Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Certifications and Accreditations
Table 7.6 List of Custom Peptide Manufacturers
Table 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
Table 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
Table 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
Table 9.1 Leading Peptide Therapeutics Contract API Manufacturers
Table 9.2 AmbioPharm: Company Overview
Table 9.3 AmbioPharm: Overview of Manufacturing Capabilities
Table 9.4 AmbioPharm: Recent Developments and Future Outlook
Table 9.5 CPC Scientific: Company Overview
Table 9.6 CPC Scientific: Overview of Manufacturing Capabilities
Table 9.7 CPC Scientific: Recent Developments and Future Outlook
Table 9.8 Creative Peptides: Company Overview
Table 9.9 Creative Peptides: Overview of Manufacturing Capabilities
Table 9.10 Creative Peptides: Recent Developments and Future Outlook
Table 9.11 CSBio: Company Overview
Table 9.12 CSBio: Overview of Manufacturing Capabilities
Table 9.13 CSBio: Recent Developments and Future Outlook
Table 9.14 Bachem: Company Overview
Table 9.15 Bachem: Overview of Manufacturing Capabilities
Table 9.16 Bachem: Recent Developments and Future Outlook
Table 9.17 BCN Peptides: Company Overview
Table 9.18 BCN Peptides: Overview of Manufacturing Capabilities
Table 9.19 BCN Peptides: Recent Developments and Future Outlook
Table 9.20 CordenPharma: Company Overview
Table 9.21 CordenPharma: Overview of Manufacturing Capabilities
Table 9.22 CordenPharma: Recent Developments and Future Outlook
Table 9.23 PolyPeptide: Company Overview
Table 9.24 PolyPeptide: Overview of Manufacturing Capabilities
Table 9.25 PolyPeptide: Recent Developments and Future Outlook
Table 9.26 Senn Chemicals: Company Overview
Table 9.27 Senn Chemicals: Overview of Manufacturing Capabilities
Table 9.28 Auspep: Company Overview
Table 9.29 Auspep: Overview of Manufacturing Capabilities
Table 9.30 Auspep: Recent Developments and Future Outlook
Table 9.31 Chinese Peptide: Company Overview
Table 9.32 Chinese Peptide: Overview of Manufacturing Capabilities
Table 9.33 Hybio Pharmaceuticals: Company Overview
Table 9.34 Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 9.35 Peptide Institute: Company Overview
Table 9.36 Peptide Institute: Overview of Manufacturing Capabilities
Table 9.37 ScinoPharm: Company Overview
Table 9.38 ScinoPharm: Overview of Manufacturing Capabilities
Table 10.1 Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations, Pre-2019-2023
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 10.3 Peptide Therapeutics Contract API Manufacturers: List of Recent Expansions, Pre-2019-2023
Table 10.4 Peptide Therapeutics Contract API Manufacturers: List of Planned Upcoming Expansions
Table 14.1 Peptide Therapeutics Contract API Manufacturers: Information on Total Installed Capacity (Sample Dataset)
Table 14.2 Peptide Therapeutics Contract API Manufacturing: Average Capacity based on Company Size (Sample Dataset)
Table 14.3 Peptide Therapeutics Contract API Manufacturing Capacity: Average Share Based on Synthesis Method (Sample Dataset)
Table 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 15.1 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.2 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.3 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.4 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.5 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.6 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.7 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.8 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.9 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 24.1 Ascendia Pharmaceuticals: Company Snapshot
Table 24.2 Almac: Company Snapshot
Table 24.3 NUMAFERM: Company Snapshot
Table 24.4 Sekisui: Company Snapshot
Table 24.5 Previtalica: Company Snapshot
Table 25.1 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Establishment
Table 25.2 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Entrance
Table 25.3 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Company Size
Table 25.4 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Headquarters
Table 25.5 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Product
Table 25.6 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of API Manufactured
Table 25.7 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Scale of Operation
Table 25.8 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Service Offered
Table 25.9 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Peptide Synthesis Method
Table 25.10 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Chemical Synthesis Method
Table 25.11 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Peptide Modification
Table 25.12 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Purification Technology Used
Table 25.13 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 25.14 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Geographical Presence (Region)
Table 25.15 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Table 25.16 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)
Table 25.17 Partnerships andCollaborations: Cumulative Year-wise Trend, Pre-2019-2023
Table 25.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 25.20 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 25.21 Partnerships and Collaborations: Distribution by Scale of Operation
Table 25.22 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 25.23 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Table 25.24 Most Active Players: Distribution by Number of Partnerships
Table 25.25 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 25.26 Partnerships and Collaborations: Local and International Agreements
Table 25.27 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023
Table 25.28 Recent Expansions: Distribution by Type of Expansion
Table 25.29 Recent Expansions: Distribution by Year and Type of Expansion
Table 25.30 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 25.31 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 25.32 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 25.33 Most Active Players: Distribution by Number of Expansions
Table 25.34 Recent Expansions: Distribution by Geography (Country)
Table 25.35 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 25.36 Clinical Trial Analysis: Year-wise Trend of Number of Patients Enrolled by Trial Registration Year
Table 25.37 Clinical Trial Analysis:Distribution by Trial Phase
Table 25.38 Clinical Trial Analysis:Distribution by Trial Phase and Number of Patients Enrolled
Table 25.39 Clinical Trial Analysis:Distribution by Trial Status
Table 25.40 Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status
Table 25.41 Clinical Trial Analysis:Distribution by Therapeutic Area
Table 25.42 Clinical Trial Analysis:Distribution by Mechanism of Action
Table 25.43 Clinical Trial Analysis:Distribution by Trial Registration Year and Mechanism of Action
Table 25.44 Clinical Trial Analysis:Distribution by Type of Sponsor / Collaborator
Table 25.45 Clinical Trial Analysis:Distribution by Type of Patient Allocation Model Used
Table 25.46 Clinical Trial Analysis:Distribution by Type of Trial Masking Adopted
Table 25.47 Clinical Trial Analysis:Distribution by Type of Intervention Model
Table 25.48 Clinical Trial Analysis:Distribution by Trial Purpose
Table 25.49 Most Active Industry Players:Distribution by Number of Clinical Trials
Table 25.50 Most Active Non-industryPlayers: Distribution by Number of Clinical Trials
Table 25.51 Clinical Trial Analysis:Distribution of Clinical Trials by Geography
Table 25.52 Clinical Trial Analysis:Distribution of Clinical Trials by Geography and Trial Status
Table 25.53 Clinical Trial Analysis:Distribution by Geography and Therapeutic Area
Table 25.54 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography
Table 25.55 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography and Trial Status
Table 25.56 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities
Table 25.57 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Table 25.58 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Table 25.59 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia Pacific and Rest of the World
Table 25.60 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.61 Global Clinical Demand forPeptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Future Estimates (2024-2035) (Kilograms)
Table 25.62 Clinical Demand for PeptideTherapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035
Table 25.63 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)
Table 25.64 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)
Table 25.65 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)
Table 25.66 Global Commercial Demandfor Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.67 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Mechanism of Action (specific to GLP-1),
Table 25.68 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035)
Table 25.69 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 based Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-
Table 25.70 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035
Table 25.71 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)
Table 25.72 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 25.73 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (liters)
Table 25.74 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (liters)
Table 25.75 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (liters)
Table 25.76 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing
Table 25.77 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (liters)
Table 25.78 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)
Table 25.79 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 25.80 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Table 25.81 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Table 25.82 Global Peptide TherapeuticsContract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.83 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 25.84 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 25.85 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035
Table 25.86 Peptide Therapeutics Contract API Manufacturing Market for Type of Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.87 Peptide Therapeutics Contract API Manufacturing Market for Type of Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.88 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.89 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.90 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.91 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035
Table 25.92 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-
Table 25.93 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.94 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.95 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035
Table 25.96 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.97 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)
Table 25.98 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)
Table 25.99 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)
Table 25.100 Peptide TherapeuticsContract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.101 Peptide TherapeuticsContract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.102 Peptide TherapeuticsContract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.103 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)
Table 25.104 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)
Table 25.105 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)
Table 25.106 Peptide TherapeuticsContract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.107 Peptide TherapeuticsContract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.108 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.109 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.110 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.111 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.112 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.113 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Recent Developments and Initiatives
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Demand Analysis
Figure 4.5 Executive Summary: Capacity Analysis
Figure 4.6 Executive Summary: Total Cost of Ownership
Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (I/II)
Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (II/II)
Figure 5.1 Methods of Peptide Synthesis
Figure 5.2 Latest Technologies for Peptide Synthesis
Figure 5.3 Peptide Modification Techniques
Figure 5.4 Types of Third-Party Service Providers
Figure 6.1 Regulatory Agencies Governing Peptide Manufacturing in the US
Figure 7.1 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
Figure 7.2 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Entrance of Peptide API Contract Manufacturers
Figure 7.3 Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
Figure 7.4 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
Figure 7.5 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
Figure 7.6 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of API Manufactured
Figure 7.7 Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
Figure 7.8 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Services Offered
Figure 7.9 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method
Figure 7.10 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification
Figure 7.11 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
Figure 7.12 Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Certifications and Accreditations
Figure 7.13 Peptide Therapeutics Contract API Manufacturers: Distribution by Geographical Presence (Region)
Figure 7.14 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Figure 7.15 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)
Figure 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
Figure 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
Figure 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
Figure 9.1 AmbioPharm: Service Portfolio
Figure 9.2 CPC Scientific: Service Portfolio
Figure 9.3 Creative peptides: Service Portfolio
Figure 9.4 CSBio: Service Portfolio
Figure 9.5 Bachem: Service Portfolio
Figure 9.6 BCN Peptide: Service Portfolio
Figure 9.7 CordenPharma: Service Portfolio
Figure 9.8 PolyPeptide: Service Portfolio
Figure 9.9 Senn Chemicals: Service Portfolio
Figure 9.10 Auspep: Service Portfolio
Figure 9.11 Chinese Peptide: Service Portfolio
Figure 9.12 Hybio Pharmaceuticals: Service Portfolio
Figure 9.13 Peptide Institute: Service Portfolio
Figure 9.14 ScinoPharm: Service Portfolio
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wiseTrend, Pre-2019-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Typeof Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 10.7 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.10 Partnerships and Collaborations: Local and International Agreements
Figure 10.11 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023
Figure 10.12 Recent Expansions: Distribution by Type of Expansion
Figure 10.13 Recent Expansions: Distribution by Year and Type of Expansion
Figure 10.14 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 10.15 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 10.16 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Figure 10.17 Most Active Players: Distribution by Number of Expansions
Figure 10.18 Recent Expansions: Distribution by Geography (Country)
Figure 10.19 Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
Figure 10.20 Continuous Flow Technology: Advantages and Disadvantages
Figure 10.21 Green Chemistry: Advantages and Disadvantages
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 11.7 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.10 Clinical Trial Analysis: Distribution by Mechanism of Action
Figure 11.11 Clinical Trial Analysis: Distribution by Trial Registration Year and Mechanism of Action
Figure 11.12 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.13 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 11.14 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 11.15 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 11.16 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 11.17 Most Active Industry Players: Distribution by Number of Clinical Trials
Figure 11.18 Most Active Non-industry Players: Distribution by Number of Clinical Trials
Figure 11.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 11.21 Clinical Trial Analysis: Distribution by Geography and Therapeutic Area
Figure 11.22 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 11.23 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 12.1 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities
Figure 12.2 Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Figure 12.3 Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Figure 12.4 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia-Pacific
Figure 13.1 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.2 Global Clinical Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.3 Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035
Figure 13.4 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)
Figure 13.5 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)
Figure 13.6 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)
Figure 13.7 Global Commercial Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.8 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by to GLP-1 Mechanism of Action, 2024 and 2035
Figure 13.9 Commercial Demand for Peptide Therapeutics Contract API Manufacturing forGLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.10 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.11 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035 (Kilograms)
Figure 13.12 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)
Figure 14.1 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size
Figure 14.2 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (Liters)
Figure 14.3 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (Liters)
Figure 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Liters)
Figure 14.5 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 14.6 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (Liters)
Figure 16.1 Make versus Buy Decision Making Framework
Figure 16.2 Make versus Buy Decision Making: Possible Scenario
Figure 17.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 17.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 17.3 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)
Figure 17.4 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 17.5 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Figure 17.6 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Figure 18.1 Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.2 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 18.3 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 19.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035
Figure 19.2 Peptide Therapeutics Contract API Manufacturing Market for Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3 Peptide Therapeutics Contract API Manufacturing Market for Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.4 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.5 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.6 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035
Figure 20.2 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.4 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035
Figure 21.2 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.3 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)
Figure 21.4 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)
Figure 21.5 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)
Figure 21.6 Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.7 Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.8 Peptide Therapeutics Contract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.9 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)
Figure 21.10 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)
Figure 21.11 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)
Figure 21.12 Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.13 Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.14 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.15 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.16 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.17 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.18 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.19 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 22.1 Contract Peptide API Manufacturing: SWOT Analysis
Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1 Concluding Remarks: Overall Market Landscape (I/II)
Figure 23.2 Concluding Remarks: Overall Market Landscape (I/II)
Figure 23.3 Concluding Remarks: Recent Developments (I/II)
Figure 23.4 Concluding Remarks: Recent Developments (I/II)
Figure 23.5 Concluding Remarks: Clinical Trial Analysis
Figure 23.6 Concluding Remarks: Demand Analysis
Figure 23.7 Concluding Remarks: Capacity Analysis
Figure 23.8 Concluding Remarks: Likely Partner Analysis
Figure 23.9 Concluding Remarks: Total Cost of Ownership (USD Million)
Figure 23.10 Concluding Remarks: Market Sizing and Opportunity Analysis

Product Code: RA100326

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

The peptide synthesis market is valued at USD 2.5 billion in 2023 growing at a CAGR of 5.46% during the forecast period 2023-2035.

Peptides serve as signaling molecules that bind to specific receptors on cell surfaces, initiating intracellular effects that regulate physiological functions and metabolic synthesis of various components. Their significance as therapeutic candidates have grown due to enhanced metabolic stability, target specificity, and affinity. Unlike small molecule drugs and biologics, peptide-based therapeutics present unique challenges in pharmacological research, analytical/process development, impurity research, and structure recognition. The peptide synthesis market has evolved significantly in recent years, driven by the popularity of peptide therapeutics. Currently, over 80 peptide therapeutics have been approved globally for treating various chronic diseases such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. Moreover, since 2015, more than 630 clinical trials have been underway to evaluate the therapeutic effectiveness of peptide-based therapies. Further, the increasing research activity and demand for peptide-based treatments have led developers to expand their capabilities and upgrade manufacturing equipment. However, peptide synthesis faces challenges including production capacity shortages, prompting developers to outsource complex manufacturing processes to contract service providers to reduce costs and time to market. Pharmaceutical and biotechnology companies are actively collaborating with contract manufacturing organizations (CMOs) offering advanced technology platforms to improve the bioavailability of peptide drugs and enhance synthesis efficacy. Outsourcing demand surged with the entry of semaglutide generics into the peptide synthesis market. GLP-1 peptide API contract manufacturing demand notably rose at a rate of 37% annually during 2017-2023 due to its benefits in treating metabolic disorders like type II diabetes and obesity. These factors present lucrative opportunities for contract manufacturers in the peptide synthesis market in the near future.

Key Market Segments

Type of Synthesis Method Used

Chemical Synthesis Method

Non-Chemical Synthesis Method

Type of Chemical Synthesis Method

Liquid Phase Peptide Synthesis

Solid Phase Peptide Synthesis

Hybrid Phase Peptide Synthesis

Company (CMO) Size

Small

Mid-sized

Large

Geography

North America

Europe

Asia-Pacific and Rest of the World

Research Coverage:

The report studies the peptide synthesis market based on type of synthesis method used, type of chemical synthesis method, company (CMO) size and key geographical regions

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to three major regions

A comprehensive examination of the current market landscape of contract manufacturers providing peptide synthesis services, including various pertinent parameters such as establishment year, entry year into peptide API manufacturing, company size (number of employees), headquarters location, product type (API, intermediates, FDF / fill-finish), API type, services offered, peptide synthesis method, peptide modification type, purification technology, regulatory certifications, geographical presence, and location of peptide API manufacturing facilities.

Detailed company competitiveness evaluation of peptide synthesis contract manufacturers, considering supplier strength and company competitiveness in terms of type of API, type of service offered, type of synthesis method, purification technique used, scale of operation and geographical presence. In addition, number of peptide modification services offered has also been considered. A comprehensive review of recent developments and initiatives undertaken by contract manufacturers in the peptide synthesis industry. This includes a focus on partnerships, collaborations, and expansion initiatives occurring in the peptide synthesis market from 2014 to October 2023.

An in-depth analysis of ongoing and planned studies concentrating on peptide therapeutics. This analysis encompasses various parameters such as trial registration year, number of enrolled patients, trial phase, status, study design (masking type, intervention model, primary purpose), sponsor/collaborator type, therapeutic area, mechanism of action, clinical trial centers, geography, and patient population.

A detailed examination of the capabilities of peptide synthesis companies in different regions. This analysis considers parameters like the number of Contract Manufacturing Organizations (CMOs), clinical sites, clinical trials, enrolled patients, peptide manufacturing facilities, demand for peptide therapeutics, and installed capacity.

Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on parameters such as target patient population, dosing frequency, and dose strength.

An estimate of the global installed capacity of contract manufacturers in the peptide synthesis market. This analysis considers data reported by industry stakeholders and factors in the distribution of peptide production capacity among companies of different sizes (small, mid-sized, and large), operational scale (preclinical/clinical and commercial), location of manufacturing facility (North America, Europe, and Asia Pacific), and synthesis method (solid phase peptide synthesis and liquid phase peptide synthesis).

An analysis highlighting potential strategic partners based on the likelihood of collaborating with peptide therapeutics developers. These potential partners are shortlisted considering parameters like pipeline strength, pipeline maturity, year of establishment, and company size.

A qualitative examination outlining the key factors that peptide drug developers must consider when deciding whether to produce their products in-house or enlist the services of a Contract Manufacturing Organization (CMO).

An in-depth, region-specific analysis of the total cost of ownership associated with engaging a peptide contract manufacturing service provider. This analysis provides an estimate of both direct and indirect expenses across 10 relevant parameters over a 20-year timeframe.

A review of regulatory guidelines pertaining to peptide synthesis, with a focus on the variations observed across different regions such as the US, Europe, Australia, China, India, Japan, and South Korea. This discussion also addresses the regulatory challenges faced by peptide synthesis companies.

A discourse on industry-related trends, key drivers, and challenges within the peptide synthesis sector, structured within a SWOT framework. This analysis includes a Harvey ball assessment to highlight the relative impact of each SWOT parameter on industry dynamics.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the peptide synthesis market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

AmbioPharm

CPC Scientific

Creative Peptides

CSBio

Bachem

BCN Peptide

CordenPharma

Senn Chemicals

PolyPeptide

Auspep

Chinese Peptide Company

Hybio Pharmaceuticals

Peptide Institute

ScinoPharm

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
- 2.6.1. Demographics
- 2.6.2. Economic Factors
- 2.6.3. Government Regulations
- 2.6.4. Supply Chain
- 2.6.5. COVID Impact / Related Factors
- 2.6.6. Market Access
- 2.6.7. Healthcare Policies
- 2.6.8. Industry Consolidation
2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Peptides
- 5.2.1. Structural Analysis of Peptides
- 5.2.2. Classification of Peptides
- 5.2.3. Peptide Synthesis
- 5.2.4. Emerging Technologies for Peptide Synthesis
- 5.2.5. Peptide Modification
  - 5.2.5.1. N-terminal Modification
  - 5.2.5.2. Internal Modification
  - 5.2.5.3. C-terminal Modification
  - 5.2.5.4. Other Modifications
- 5.2.6. Peptide Purification
  - 5.2.6.1. Peptide Purity Guidelines
5.3. Overview of Contract Manufacturing
- 5.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
- 5.3.2. General Considerations for Selecting a CMO Partner
- 5.3.3. Advantages of Outsourcing Manufacturing Operations
- 5.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
5.4. Future Perspectives

6. REGULATORY LANDSCAPE

6.1. Chapter Overview
6.2. Regulatory Scenario: North America
- 6.2.1. Scenario in The US
  - 6.2.1.1. Overview
  - 6.2.1.2. General Guidelines for Peptide Manufacturing
6.3. Regulatory Scenario: Europe
- 6.3.1. Scenario in Europe
  - 6.3.1.1. Overview
  - 6.3.1.2. General Guidelines
- 6.3.2. Scenario in The UK
  - 6.3.2.1. Overview
  - 6.3.2.2. General Guidelines for Peptide Manufacturing
6.4. Regulatory Scenario: Asia-Pacific
- 6.4.1. Overview
- 6.4.2. Scenario in Australian
  - 6.4.2.1. General Guidelines for Peptide Manufacturing
- 6.4.3. Scenario in Chinese
  - 6.4.3.1. General Guidelines for Peptide Manufacturing
  - 6.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
- 6.4.4. Scenario in India
  - 6.4.4.1. General Guidelines for Peptide Manufacturing
  - 6.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
- 6.4.5. Scenario in Japan
  - 6.4.5.1. General Guidelines for Peptide Manufacturing
- 6.4.6. Scenario in South Korea
  - 6.4.6.1. General Guidelines for Peptide Manufacturing
6.5. Challenges Associated with Peptide Manufacturing

7. MARKET LANDSCAPE

7.1 Chapter Overview
7.2 Peptide Therapeutics Contract API Manufacturing: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Year of Entrance of Peptide API Contract Manufacturers
- 7.2.3. Analysis by Company Size
- 7.2.4. Analysis by Location of Headquarters
- 7.2.5. Analysis by Type of Product
- 7.2.6. Analysis by Type of API Manufactured
- 7.2.7. Analysis by Scale of Operation
- 7.2.8. Analysis by Type of Services Offered
- 7.2.9. Analysis by Type of Peptide Synthesis Method
- 7.2.10. Analysis by Type of Peptide Modification
- 7.2.11. Analysis by Type of Purification Technology Used
- 7.2.12. Analysis by Regulatory Certifications and Accreditations
- 7.2.13. Analysis by Geographical Presence
- 7.2.14. Analysis by Location of Peptide API Manufacturing Facilities
7.3. List of Custom Peptide Manufacturers

8. COMPANY COMPETITIVENSS ANALYSIS

8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Company Competitiveness Analysis
- 8.4.1 Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
- 8.4.2 Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
- 8.4.2 Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

9. COMPANY PROFILES

9.1 Chapter Overview
9.2. Peptide Therapeutics Contract API Manufacturers based in North America
- 9.2.1. AmbioPharm
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Service Portfolio
  - 9.2.1.3. Manufacturing Facilities and Capabilities
  - 9.2.1.4. Recent Developments and Future Outlook
- 9.2.2. CPC Scientific
  - 9.2.2.1. Company Overview
  - 9.2.2.2. Service Portfolio
  - 9.2.2.3. Manufacturing Facilities and Capabilities
  - 9.2.2.4. Recent Developments and Future Outlook
- 9.2.3. Creative Peptides
  - 9.2.3.1. Company Overview
  - 9.2.3.2. Service Portfolio
  - 9.2.3.3. Manufacturing Facilities and Capabilities
  - 9.2.3.4. Recent Developments and Future Outlook
- 9.2.4. CSBio
  - 9.2.4.1. Company Overview
  - 9.2.4.2. Service Portfolio
  - 9.2.4.3. Manufacturing Facilities andCapabilities
  - 9.2.4.4. Recent Developments and Future Outlook
9.3. Peptide Therapeutics Contract API Manufacturers based in Europe
- 9.3.1. Bachem
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Service Portfolio
  - 9.3.1.3. Manufacturing Facility and Capabilities
  - 9.3.1.4. Recent Developments and Future Outlook
- 9.3.2. BCN Peptides
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Service Portfolio
  - 9.3.2.3. Manufacturing Facility andCapabilities
  - 9.3.2.4. Recent Development and Future Outlook
- 9.3.3. CordenPharma
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Service Portfolio
  - 9.3.3.3. Manufacturing Facility and Capabilities
  - 9.3.3.4. Recent Developments and Future Outlook
- 9.3.4. PolyPeptide
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Service Portfolio
  - 9.3.4.3. Manufacturing Facilities and Capabilities
  - 9.3.4.4. Recent Developments and Future Outlook
- 9.3.5. Senn Chemicals
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Service Portfolio
  - 9.3.5.3. Manufacturing Facilities and Capabilities
  - 9.3.5.4. Recent Developments and Future Outlook
9.4. Peptide Therapeutics Contract API Manufacturers based in Asia-Pacific
- 9.4.1. Auspep
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Service Portfolio
  - 9.4.1.3. Manufacturing Facilities and Capabilities
  - 9.4.1.4. Recent Developments and Future Outlook
- 9.4.2. Chinese Peptide
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Service Portfolio
  - 9.4.2.3. Manufacturing Facilities and Capabilities
  - 9.4.2.4. Recent Developments and Future Outlook
- 9.4.3. Hybio Pharmaceutical
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Service Portfolio
  - 9.4.3.3. Manufacturing Facilities and Capabilities
  - 9.4.3.4. Recent Developments and Future Outlook
- 9.4.4. Peptide Institute
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Service Portfolio
  - 9.4.4.3. Manufacturing Facilities and Capabilities
  - 9.4.4.4. Recent Developments and Future Outlook
- 9.4.5. ScinoPharm
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Service Portfolio
  - 9.4.5.3. Manufacturing Facilities and Capabilities
  - 9.4.5.4. Recent Developments and Future Outlook

10. RECENT DEVELOPMENTS AND INITIATIVES

10.1. Chapter Overview
10.2. Partnerships and Collaborations
- 10.2.1. Partnerships Models
- 10.2.2. List of Partnerships and Collaborations
- 10.2.3. Analysis by Year of Partnership
- 10.2.4. Analysis by Type of Partnership
- 10.2.5. Analysis by Year and Type of Partnership
- 10.2.6. Analysis by Company Size and Type of Partnership
- 10.2.7. Analysis by Scale of Operation
- 10.2.8. Analysis by Scale of Operation and Type of Partnership
- 10.2.9. Analysis by Green Chemistry Integration
- 10.2.10. Most Active Players: Analysis by Number of Partnerships
- 10.2.11. Analysis by Geography
  - 10.2.11.1. Intercontinental and Intracontinental Agreements
  - 10.2.12.2. Local and International Agreements
10.3. Recent Expansion Models
- 10.3.1. Expansion Models
- 10.3.2 List of Recent Expansions
- 10.3.3. Analysis by Year of Expansion
- 10.3.4. Analysis by Type of Expansion
- 10.3.5. Analysis by Year and Type of Expansion
- 10.3.6. Analysis by Location of Expanded Facility (Region)
- 10.3.7. Analysis by Location of Expanded Facility (Country)
- 10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
- 10.3.9. Most Active Players: Analysis by Number of Expansions
- 10.3.10. Recent Expansions: Analysis by Geography (Country)
- 10.3.11. Recent Expansions: List of Planned Expansions
10.4. Emerging Peptide Synthesis Technologies
- 10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
- 10.4.2. Continuous Flow Technology
- 10.4.3. Green Chemistry

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Peptide Therapeutics: Clinical Trials Analysis
- 11.3.1. Analysis by Trial Registration Year
- 11.3.2. Analysis by Number of Patients Enrolled
- 11.3.3. Analysis by Trial Phase
- 11.3.4. Analysis by Trial Registration Year and Trial Phase
- 11.3.5. Analysis by Trial Phase and Patients Enrolled
- 11.3.6. Analysis by Trial Status
- 11.3.7. Analysis by Trial Registration Year and Trial Status
- 11.3.8. Analysis by Therapeutic Area
- 11.3.9. Analysis by Mechanism of Action
- 11.3.10. Analysis by Trial Registration Year and Mechanism of Action
- 11.3.11. Analysis by Type of Sponsor / Collaborator
- 11.3.12. Analysis by Study Design
  - 11.3.12.1. Analysis by Type of Patient Allocation Model Used
  - 11.3.12.2. Analysis by Type of Trial Masking Adopted
  - 11.3.12.3. Analysis by Type of Intervention
  - 11.3.12.4. Analysis by Trial Purpose
- 11.3.13. Most Active Players: Analysis by Number of Clinical Trials
- 11.3.14. Analysis by Geography
  - 11.3.14.1. Analysis of Clinical Trials by Geography
  - 11.3.14.2. Analysis of Clinical Trials by Geography and Trial Status
  - 11.3.14.3. Analysis of Clinical Trials by Geography and Therapeutic Area
  - 11.3.14.4. Analysis of Patients Enrolled by Geography
  - 11.3.14.5. Analysis of Patients Enrolled by Geography and Trial Status

12. REGIONAL CAPABILITY ANALYSIS

12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Landscape of Peptide Therapeutics Contract API Manufacturing Facilities
12.4. Peptide Therapeutics Contract API Manufacturing Capability in North America
12.5. Peptide Therapeutics Contract API Manufacturing Capability in Europe
12.6. Peptide Therapeutics Contract API Manufacturing Capability in Asia-Pacific

13. DEMAND ANALYSIS

13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Peptide Therapeutics Contract API Manufacturing: Overall Annual Demand
- 13.3.1. Peptide Therapeutics Contract API Manufacturing: Clinical Demand
  - 13.3.1.1. Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by Phase of Development
- 13.3.2. Peptide Therapeutics Contract API Manufacturing: Commercial Outsourced Demand
  - 13.3.2.1. Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by GLP-1 Mechanism of Action
- 13.3.3. Peptide Therapeutics Contract API Manufacturing: Analysis by Type of Peptide API Synthesis
- 13.3.4. Peptide Therapeutics Contract API Manufacturing: Analysis by Geography

14. CAPACITY ANALYSIS

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Peptide Therapeutics Contract API Manufacturing: Global Installed Capacity
- 14.3.1. Analysis by Company Size
- 14.3.2. Analysis by Scale of Operation
- 14.3.3. Analysis by Location of Manufacturing Facility
- 14.3.4. Analysis by Company Size and Location of Manufacturing Facility
- 14.3.5 Analysis by Chemical Synthesis Method
14.4. Concluding Remarks

15. LIKELY PARTNERS ANLAYSIS

15.1. Chapter Overview
15.2. Scoring Criteria and Key Assumptions
15.3. Scope and Methodology
15.4. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in North America
- 15.4.1. Most Likely Partners
- 15.4.2. Likely Partners
- 15.4.3. Least Likely Partners
15.5. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Europe
- 15.5.1. Most Likely Partners
- 15.5.2. Likely Partners
- 15.5.3. Least Likely Partners
15.6. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Asia Pacific and Rest of the World
- 15.6.1. Most Likely Partners
- 15.6.2. Likely Partners
- 15.6.3. Least Likely Partners

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

16.1. Chapter Overview
16.2. Assumptions and Parameter Definitions
16.3. Make versus Buy Decision Making Framework
- 16.3.1. Scenario 1
- 16.3.2. Scenario 2
- 16.3.3. Scenario 3
- 16.3.4. Scenario 4
16.4. Concluding Remarks

17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Key Parameters
17.4. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20
17.5. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX And OPEX, Y0 and Y20
- 17.5.1. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX, Y0
- 17.5.2. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by OPEX, Y1-Y20

18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
- 18.3.1. Scenario Analysis
  - 18.3.1.1. Conservative Scenario
  - 18.3.1.2. Optimistic Scenario
18.4. Key Market Segmentations

19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2023 and 2035
- 19.3.1. Non-chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
- 19.3.2. Chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
  - 19.3.2.1 Liquid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
  - 19.3.2.2 Solid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
  - 19.3.2.3 Hybrid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.4. Data Triangulation and Validation

20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2023 and 2035
- 20.3.1. Small Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
- 20.3.2. Mid-sized Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
- 20.3.3. Large Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation

21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY

21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 and 2035
- 21.3.1. Peptide Therapeutics Contract API Manufacturing Market in North America: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
  - 21.3.1.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America
  - 21.3.1.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America
  - 21.3.1.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America
  - 21.3.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method
  - 21.3.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method
- 21.3.2. Peptide Therapeutics Contract API Manufacturing Market in Europe: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
  - 21.3.2.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe
  - 21.3.2.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe
  - 21.3.2.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe
  - 21.3.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method
  - 21.3.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method
- 21.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
  - 21.3.3.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World
  - 21.3.3.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World
  - 21.3.3.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World
  - 21.3.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method
  - 21.3.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method
21.4. Data Triangulation and Validation

22. SWOT ANALYSIS

22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks

23. CONCLUSION

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview
24.2. Ascendia Pharmaceuticals
- 24.2.1 Company Snapshot
- 24.2.2. Interview Transcript: Robert Bloder (Chief Business Officer), Shaukat Ali (Senior Director of Scientific Affairs and Technical Marketing)
24.3. Almac
- 24.3.1 Company Snapshot
- 24.3.2. Interview Transcript: Alastair Hay (Vice President, Peptides)
24.4. NUMAFERM
- 24.4.1 Company Snapshot
- 24.4.2. Interview Transcript: Philipp Burling (Chief Financial Officer)
24.5. Sekisui XenoTech
- 24.5.1 Company Snapshot
- 24.5.2. Interview Transcript: Hideki Kubota (Senior Manager, Peptide Business Project Leader)
24.6. Previtalica
- 24.6.1 Company Snapshot
- 24.6.2. Interview Transcript: Sergiy Stupka (Founder and Owner)

ペプチド合成市場、産業動向と世界予測 (～2035年)：ペプチド合成方法別、化学合成タイプ別、受託製造組織の規模別、主要地域別

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 規制状況

第7章 市場情勢

第8章 企業の競合分析

第9章 企業プロファイル

第10章 最近の開発と取り組み

第11章 臨床試験の分析

第12章 地域能力分析

第13章 需要分析

第14章 容量分析

第15章 可能性の高いパートナーの分析

第16章 内製か外製かの意思決定の枠組み

第17章 ペプチド受託製造組織の総所有コスト

第18章 世界のペプチド治療薬原薬受託製造市場

第19章 ペプチド治療薬原薬受託製造市場、ペプチド合成方法別

第20章 ペプチド治療薬原薬受託製造市場、企業規模別

第21章 ペプチド治療薬原薬受託製造市場、地域別

第22章 SWOT分析

第23章 結論

第24章 経営陣の洞察

第25章 付録I：表形式のデータ

第26章 付録II：企業および組織のリスト

List of Tables

List of Figures

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. REGULATORY LANDSCAPE

7. MARKET LANDSCAPE

8. COMPANY COMPETITIVENSS ANALYSIS

9. COMPANY PROFILES

10. RECENT DEVELOPMENTS AND INITIATIVES

11. CLINICAL TRIAL ANALYSIS

12. REGIONAL CAPABILITY ANALYSIS

13. DEMAND ANALYSIS

14. CAPACITY ANALYSIS

15. LIKELY PARTNERS ANLAYSIS

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET

19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE

21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY

22. SWOT ANALYSIS

23. CONCLUSION

24. EXECUTIVE INSIGHTS

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章調査手法

第3章経済およびその他のプロジェクト特有の考慮事項

第4章エグゼクティブサマリー

第5章イントロダクション

第6章規制状況

第7章市場情勢

第8章企業の競合分析

第9章企業プロファイル

第10章最近の開発と取り組み

第11章臨床試験の分析

第12章地域能力分析

第13章需要分析

第14章容量分析

第15章可能性の高いパートナーの分析

第16章内製か外製かの意思決定の枠組み

第17章ペプチド受託製造組織の総所有コスト

第18章世界のペプチド治療薬原薬受託製造市場

第19章ペプチド治療薬原薬受託製造市場、ペプチド合成方法別

第20章ペプチド治療薬原薬受託製造市場、企業規模別

第21章ペプチド治療薬原薬受託製造市場、地域別

第23章結論

第24章経営陣の洞察

第25章付録I：表形式のデータ

第26章付録II：企業および組織のリスト